Lack of Serologic Evidence of Infection Among Health Care Personnel and Other Contacts of First 2 Confirmed Patients With COVID-19 in Illinois, 2020
| Autor: | E. Matt Charles, Isaac Ghinai, Mohammed Ata Ur Rasheed, Natalie J. Thornburg, Alison M. Binder, Chantel Hoskin Snelling, Pearl Quartey-Kumapley, Jennifer R. Verani, Massimo Pacilli, Mujeeb Zafer, Kiran Joshi, Demian Christiansen, Marc Fischer, Brandi Freeman, Tristan D. McPherson, Jacqueline Korpics, Darcie Moeller, Deborah L. Rudd, Rachel Rubin, John T. Watson, Heather Reese, Megan J. Wallace, Sandra Lester, Max W Jacobs, Megan T. Patel, Kelly A. Walblay, Jennifer C. Hunter, Stephanie R. Black, Chen Wang, Hannah L. Kirking, Judy Kauerauf, Polly Davenport, Kristin M. Anderson, Vishal S. Disari, Marielle J Fricchione, Claire M Midgley, Jennifer E Layden |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Health Personnel Enzyme-Linked Immunosorbent Assay 01 natural sciences Risk Assessment Virus Serology 03 medical and health sciences 0302 clinical medicine ABO blood group system Occupational Exposure Health care Epidemiology Pandemic medicine Humans 030212 general & internal medicine 0101 mathematics Intensive care medicine Pandemics Personal Protective Equipment business.industry Transmission (medicine) SARS-CoV-2 Research 010102 general mathematics Public Health Environmental and Occupational Health COVID-19 Female Illinois Contact Tracing business Contact tracing |
| Zdroj: | Public Health Rep |
| ISSN: | 1468-2877 |
| Popis: | Objectives Widespread global transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), continues. Many questions remain about asymptomatic or atypical infections and transmission dynamics. We used comprehensive contact tracing of the first 2 confirmed patients in Illinois with COVID-19 and serologic SARS-CoV-2 antibody testing to determine whether contacts had evidence of undetected COVID-19. Methods Contacts were eligible for serologic follow-up if previously tested for COVID-19 during an initial investigation or had greater-risk exposures. Contacts completed a standardized questionnaire during the initial investigation. We classified exposure risk as high, medium, or low based on interactions with 2 index patients and use of personal protective equipment (PPE). Serologic testing used a SARS-CoV-2 spike enzyme-linked immunosorbent assay on serum specimens collected from participants approximately 6 weeks after initial exposure to either index patient. The 2 index patients provided serum specimens throughout their illness. We collected data on demographic, exposure, and epidemiologic characteristics. Results Of 347 contacts, 110 were eligible for serologic follow-up; 59 (17% of all contacts) enrolled. Of these, 53 (90%) were health care personnel and 6 (10%) were community contacts. Seventeen (29%) reported high-risk exposures, 15 (25%) medium-risk, and 27 (46%) low-risk. No participant had evidence of SARS-CoV-2 antibodies. The 2 index patients had antibodies detected at dilutions >1:6400 within 4 weeks after symptom onset. Conclusions In serologic follow-up of the first 2 known patients in Illinois with COVID-19, we found no secondary transmission among tested contacts. Lack of seroconversion among these contacts adds to our understanding of conditions (ie, use of PPE) under which SARS-CoV-2 infections might not result in transmission and demonstrates that SARS-CoV-2 antibody testing is a useful tool to verify epidemiologic findings. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|